Lipids & metabolic liver disease
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis
Authors' conclusion
GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH.
Study context
- Population
- Patients with MASLD/MASH
- Participants
- 2,600 patients25 randomized controlled trials (RCTs)
- Comparison
- GLP-1RAs vs placebo or active agents
- Outcome
- Liver fat content by imaging
- Follow-up
- Median 24 weeks
Methodological detailsrandom-effect model
- Random-effect model
Pooled result
As reported in the abstract
Significant reduction in liver fat content (LFC) with GLP-1RAs
5.21%
Further pooled results
Liver histology
- Significant improvements in steatosis, hepatocellular ballooning and lobular inflammation; nonsignificant improvement in fibrosis; evidence for tirzepatide more robust than for semaglutide and liraglutide
Serum liver enzymes
- Significantly decreased ALT, AST and GGT vs control
Liver stiffness
- Significantly improved, semaglutide most obvious effect
Safety
- No drug-related adverse effects involving the liver observed
Original publication
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. Published 9 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →